Rajyalakshmi Luthra

发表

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

Keyur P. Patel, Rashmi Kanagal-Shamanna, Koji Sasaki, 2019, Blood.

Validation and implementation of next-generation sequencing technologies in a clinical molecular diagnostic laboratory

Rajyalakshmi Luthra, Rajesh R. Singh, R. Luthra, 2015 .

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics

Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, K. Aldape, 2014, Modern Pathology.

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

Razelle Kurzrock, David S. Hong, Rajyalakshmi Luthra, 2012, Oncotarget.

Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential

Rajyalakshmi Luthra, L. Jeffrey Medeiros, Mark J. Routbort, 2016 .

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, 2010, Modern Pathology.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mark Brandt, Susan O'Brien, B Nebiyou Bekele, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Razelle Kurzrock, J Jack Lee, Rajyalakshmi Luthra, 2014, Cell reports.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lisa M McShane, Robin D Harrington, Chih-Jian Lih, 2017, The Journal of molecular diagnostics : JMD.

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

Pedro Cano, Rajyalakshmi Luthra, P. Cano, 2004, BMC Cancer.

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Razelle Kurzrock, Sijin Wen, Rajyalakshmi Luthra, 2012, Clinical Cancer Research.

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Yuan Qi, Ken Chen, Zechen Chong, 2015, Clinical chemistry.

Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.

Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, K. Aldape, 2013, The Journal of molecular diagnostics : JMD.

Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.

Ronald Abraham, Stanley R. Hamilton, Rajyalakshmi Luthra, 2010, The Journal of molecular diagnostics : JMD.

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Susan O'Brien, Jorge Cortes, Rajyalakshmi Luthra, 2005, Clinical Cancer Research.

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

Ken H. Young, Rashmi Kanagal-Shamanna, Rajyalakshmi Luthra, 2015, Leukemia research.

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Razelle Kurzrock, David S. Hong, Rajyalakshmi Luthra, 2011, Molecular Cancer Therapeutics.

Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Rajyalakshmi Luthra, K. Patel, F. Ravandi, 2011, American journal of clinical pathology.

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Razelle Kurzrock, Rajyalakshmi Luthra, Apostolia M Tsimberidou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.